Strategies for antimicrobial drug delivery to biofilm

Current Pharmaceutical Design

Volumn 21, Issue 1, 2015, Pages 43-66

  Martin, Claire ^a   Low, Wan Li ^a   Gupta, Abhishek ^a   Mohd, Mohd Cairul Iqbal Amin ^b   Radecka, Iza ^a   Britland, Stephen T ^a   Raj, Prem ^a   Kenward, Ken ^a  

^a UNIVERSITY OF WOLVERHAMPTON   (United Kingdom)

^b UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

Author keywords

Antimicrobial agents; Biofilm; Controlled release; Copper; Cyclodextrins; Dendrimers; Drug delivery systems; Gold; Iron salts; Liposomes; Micro and nanoparticles; Microemulsions; Silver; Smart polymers; Solid lipid nanoparticles; Zinc

Indexed keywords

ANTIINFECTIVE AGENT; COPPER NANOPARTICLE; CYCLODEXTRIN; DENDRIMER; EXTRACELLULAR POLYMERIC SUBSTANCE; GOLD NANOPARTICLE; IRON SALT; LIPOSOME; METAL NANOPARTICLE; POLYMER; SILVER; SILVER NANOPARTICLE; SOLID LIPID NANOPARTICLE; SUPERPARAMAGNETIC IRON OXIDE NANOPARTICLE; UNCLASSIFIED DRUG; ZINC; EMULSION;

ANTIMICROBIAL ACTIVITY; ARTICLE; BIOFILM; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG FORMULATION; HUMAN; MICROEMULSION; NONHUMAN; QUORUM SENSING; ANIMAL; ANTIBIOTIC RESISTANCE; CELL COMMUNICATION; CELL COUNT; DRUG EFFECTS; EMULSION; PHYSIOLOGY;

ANIMALS; ANTI-INFECTIVE AGENTS; BIOFILMS; CELL COMMUNICATION; CELL COUNT; DRUG DELIVERY SYSTEMS; DRUG RESISTANCE, MICROBIAL; EMULSIONS; HUMANS; METAL NANOPARTICLES; QUORUM SENSING;

EID: 84919740873     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666140905123529     Document Type: Article

References (199)

1. de la Fuente-Núñez C, Reffuveille F, Fernández L, et al. Bacterial biofilm development as a multicellular adaptation: Antibiotic resistance and new therapeutic strategies. Curr Opin Microbiol 2013; 16: 580-9.
2. Martin C, Low WL, Amin MCIM, et al. Current trends in the development of wound dressings, biomaterials and devices. Pharm Pat Anal 2013; 2: 341-59.
3. Gao G, Lange D, Hilpert K, et al. The biocompatibility and biofilm resistance of implant coatings based on hydrophilic polymer brushes conjugated with antimicrobial peptides. Biomaterials 2011; 32: 3899-909.
4. Lindsay D, von Holy A. Bacterial biofilms within the clinical setting: What healthcare professionals should know. J Hosp Infect 2006; 64: 313-25.
5. Jefferson KK. What drives bacteria to produce a biofilm? FEMS Microbiol Lett 2004; 236: 163-73.
6. Donlan RM. Biofilms: Microbial life on surfaces. Emerging Infect Dis 2002; 8: 881-90.
7. Donlan RM, Costerton JW. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 2002; 15: 167-93.
8. O'Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. Ann Rev Microbiol 2000; 54: 49-79.
9. Arciola CR, Campoccia D, Speziale P, et al. Biofilm formation in Staphylococcus implant infections. A review of molecular mechanisms and implications for biofilm-resistant materials. Biomaterials 2012; 33: 5967-82.
10. Simões M, Simões LC, Vieira MJ, et al. A review of current and emergent biofilm control strategies. LWT-Food Sci Technol 2010; 43: 573-83.
11. Hall-Stoodley L, Costerton JW, Stoodley P. Bacterial biofilms: From the natural environment to infectious diseases. Nat Rev Microbiol 2004; 2: 95-108.
12. Boumis E, Gesu G, Menichetti F, et al. Consensus document on controversial issues in the diagnosis and treatment of bloodstream infections and endocarditis. Int J Infect Dis 2010; 14: S23-38.
13. Tré-Hardy M, Traore H, El Manssouri N, et al. Evaluation of longterm co-administration of tobramycin and clarithromycin in a mature biofilm model of cystic fibrosis clinical isolates of Pseudomonas aeruginosa. Int J Antimicrobl Agent 2009; 34: 370-4.
14. Tenke P, Riedl CR, Jones GLl. Bacterial biofilm formation on urologic devices and heparin coating as preventative strategy. Int J Antimicrob Agent 2004; 23S1: S67-74.
15. Wang XF, Zhang SL, Zhu LY, et al. Enhancement of antibacterial activity of tilmicosin against Staphylococcus aureus by solid lipid nanoparticles in vitro and in vivo. Vet J 2012; 191: 115-20.
16. Hengzhuang W, Wu H, Ciofu O, et al. In vivo pharmacokinetics/pharmacodynamics of colistin and imipenem in Pseudomonas aeruginosa biofilm infection. Antimicrob Agent Chemother 2012; 56: 2683-90.
17. Tafin UF, Corvec S, Betrisey B, et al. Role of rifampin against Propionibacterium acnes biofilm in vitro and in an experimental foreign-body infection model. Antimicrob Agent Chemother 2012; 56: 1885-91.
18. Cammarota G, Sanguinetti M, Gallo, et al. Biofilm formation by Helicobacter pylori as a target for eradication of resistant infection. Aliment Pharmacol Ther 2012; 36: 222-30.
19. Stallmann HP, Faber C, Bronckers ALJJ, et al. Osteomyelitis prevention in rabbits using antimicrobial peptide hLF1-11-or gentamicin-containing calcium phosphate cement. J Antimicrob Chemother 2004; 54: 472-6.
20. Ramanathan V, Riosa S, Al-Sharif AH, et al. Characteristics of biofilm on tunneled cuffed haemodialysis catheters in the presence and absence of clinical infection. Am J Kidney Dis 2012; 60: 976-82.
21. Lampikoski H, Aarnisalo AA, Jero J, et al. Mastoid biofilm in chronic otitis media. Otol Neurotol 2012; 33: 785-8.
22. Elgharably H, Mann E, Awad H, et al. First Evidence of Sternal Wound Biofilm following Cardiac Surgery. PLoS one 2013; 8: e70360.
23. Gardner SE, Hillis SL, Heilmann K, et al. The neuropathic diabetic foot ulcer microbiome is associated with clinical factors. Diabetes 2013; 62: 923-30.
24. de Carvalho FG, Silva DS, Hebling J, et al. Presence of mutans streptococci and Candida spp. in dental plaque/dentine of carious teeth and early childhood caries. Arch Oral Biol 2006; 51: 1024-8.
25. Oosterhof JJ, Buijssen KJ, Busscher HJ, et al. Effects of quaternary ammonium silane coatings on mixed fungal and bacterial biofilms on tracheoesophageal shunt prostheses. Appl Environ Microbiol 2006; 72: 3673-7.
26. Baena-Monroy T, Moreno-Maldonado V, Franco-Martinez F, et al. Candida albicans, Staphylococcus aureus and Streptococcus mutans colonization in patients wearing dental prosthesis. Medicina Oral, Patología Oral y Cirugía Bucal 2005; 10: E27-39.
27. Peters BM, Jabra-Rizk MA, Scheper MA, et al. Microbial interactions and differential protein expression in Staphylococcus aureus-Candida albicans dual-species biofilms. FEMS Immunol Med Microbiol 2010; 59: 493-503.
28. De Sordi L, Mühlschlegel FA. Quorum sensing and fungal-bacterial interactions in Candida albicans: a communicative network regulating microbial coexistence and virulence. FEMS Yeast Res 2009; 9: 990-9.
29. Stine AE, Nassar D, Miller JK, et al. Modelling the response of a biofilm to silver-based antimicrobial. Math Biosci 2013; 244: 29-39.
30. Kalia VC. Quorum sensing inhibitors: An overview. Biotechnol Adv 2013; 31: 224-45.
31. Han T-L, Cannon RD, Villas-Bôas SG. The metabolic basis of Candida albicans morphogenesis and quorum sensing. Fungal Genet Biol 2011; 48: 747-763.
32. Lazar V. Quorum sensing in biofilms-How to destroy the bacterial citadels or their cohesion/power? Anaerobe 2011; 17: 280-5.
33. Platt TG, Fuqua C. What's in a name? The semantics of quorum sensing. Trends Microbiol 2010; 18: 383-7.
34. Boyen F, Eeckhaut V, Van Immerseel F, et al. Quorum sensing in veterinary pathogens: Mechanisms, clinical importance and future perspectives. Vet Microbiol 2009; 135: 187-95.
35. Winzer K, Williams P. Quorum sensing and the regulation of virulence gene expression in pathogenic bacteria. Int J Med Microbiol 2001; 291: 131-43.
36. Di Cagno R, De Angelis M, Calasso M, et al. Proteomics of the bacterial cross-talk by quorum sensing. J Proteomics 2011; 74: 19-34.
37. Schertzer JW, Boulette ML, Whiteley M. More than a signal: Nonsignalling properties of quorum sensing molecules. Trends Microbiol 2009; 17: 189-95.
38. Zhang K, Ou M, Wang W, et al. Effects of quorum sensing on cell viability in Streptococcus mutans biofilm formation. Biochemical and Biophysical Research Communications 2009; 379: 933-938.
39. Kong K-F, Vuong C, Otto M. Staphylococcus quorum sensing in biofilm formation and infection. Int J Med Microbiol 2006; 296: 133-9.
40. Kjelleberg S, Molin S. Is there a role for quorum sensing signals in bacterial biofilms? Curr Opin Microbiol 2002; 5: 254-8.
41. Pritchard DI. Immune modulation by Pseudomonas aeruginosa quorum-sensing signal molecules. Int J Med Microbiol 2006; 296: 111-6.
42. Heurlier K, Dénervaud V, Haas D. Impact of quorum sensing on fitness of Pseudomonas aeruginosa. Int J Med Microbiol 2006; 296: 93-102.
43. Otto M. Quorum-sensing control in Staphylococci-a target for antimicrobial drug therapy? FEMS Microbiol Lett 2004; 241: 135-41.
44. Galloway WRJD, Hodgkinson JT, Bowden S, et al. Applications of small molecule activators and inhibitors of quorum sensing in Gram-negative bacteria. Trends Microbiol 2012; 20: 449-58.
45. Rasmussen TB, Givskov M. Quorum-sensing inhibitors as antipathogenic drugs. Int J Med Microbiol 2006; 296: 149-61.
46. Suga H, Smith KM. Molecular mechanisms of bacterial quorum sensing as a new drug target. Curr Opin Chem Biol 2003; 7: 586-91.
47. Williams P, Cámara M. Quorum sensing and environmental adaptation in Pseudomonas aeruginosa: A tale of regulatory networks and multifunctional signal molecules. Curr Opin Microbiol 2009; 12: 182-91.
48. Bauer WD, Robinson JB. Disruption of bacterial quorum sensing by other organisms. Curr Opin Biotechnol 2002; 13: 234-7.
49. Bjarnsholt T, Alhede M, Alhede M, et al. The in vivo biofilm. Trends Microbiol 2013; 21: 466-74.
50. Mah T-FC, O'Toole GA. Mechanisms of biofilm resistance to antimicrobial agents. TRENDS in Microbiology 2001; 9: 34-9.
51. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. Int J Pharm 1997; 154: 123-40.
52. Allen TM, Cullis PR. Drug delivery systems: Entering the mainstream. Science 2004; 303: 1818-22.
53. Gonnet M, Lethuaut L, Boury F. New trends in encapsulation of liposoluble vitamins. J Controlled Release 2010; 146: 276-90.
54. Kaparissides C, Alexandridou S, Kotti K, et al. Recent advances in novel drug delivery systems. J Nanotechnol Online 2006; 2: DOI: 10. 2240/azojono0111.
55. Orive G, Hernández RM, Gascón AR, et al. Drug delivery in biotechnology: present and future. Curr Opin Biotechnol 2003; 14: 659-64.
56. Park K, Mrsny RJ. Controlled drug delivery: Present and future. In Park K, Mrsny RJ, Eds. Controlled Drug Delivery. Am Chem Soc 2000; pp: 2-12.
57. Lonez C, Legat A, Vandenbranden M, et al. DiC14-amidine confers new anti-inflammatory properties to phospholipids. Cell Mol Life Sci 2008; 65: 620-30.
58. Pedrosa L, van Hell A, van Blitterswijk W, et al. Short-chain sphingolipids for enhanced cellular uptake of liposomeencapsulated amphiphilic anti-cancer drugs. BMC Proceedings 2010; 4: 39.
59. De Leeuw J, De Vijlder HC, Bjerring P, et al. Liposomes in dermatology today. J Eur Acad Dermatol Venereol 2009; 23: 505-16.
60. Lian T, Ho RJY. Trends and developments in liposome drug delivery systems. J Pharma Sci 2001; 90: 667-80.
61. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed 2006; 1: 297-315.
62. Gregoriadis G. Engineering liposomes for drug delivery: progress and problems. Trends Biotechnol 1995; 13: 527-37.
63. Mu X, Zhong Z. Preparation and properties of poly(vinyl alcohol)-stabilized liposomes. Int J Pharm 2006; 318: 55-61.
64. Ngo KX, Umakoshi H, Shimanouchi T, et al. Characterization of heat-induced interaction of neutral liposome with lipid membrane of Streptomyces griseus cell. Colloids Surfaces B 2009; 73: 399-407.
65. Catuogno C and Jones MN. The antibacterial properties of solid supported liposomes on Streptococcus oralis biofilms. Int J Pharm 2003; 257: 125-40.
66. Ahmed K, Muiruri PW, Jones GH, et al. The effect of grafted poly(ethylene glycol) on the electrophoretic properties of phospholipid liposomes and their adsorption to bacterial biofilms. Colloids Surfaces A 2001; 194: 287-96.
67. Robinson AM, Bannister M, Creeth JE, et al. The interaction of phospholipid liposomes with mixed bacterial biofilms and their use in the delivery of bactericide. Colloids Surfaces A 2001; 186: 43-53.
68. Scott MJ and Jones MN. The interaction of phospholipid liposomes with zinc citrate particles: A microcalorimetric investigation. Colloids Surfaces A 2001; 182: 247-56.
69. Catuogno C and Jones MN. The interaction of cationic and anionic vesicles with zinc citrate dispersions. Colloids and Surfaces A: Physicochem Engineering Aspects 2000; 163: 165-76.
70. Kim HJ, Michael Gias EL and Jones MN. The adsorption of cationic liposomes to Staphylococcus aureus biofilms. Colloids Surf A 1999; 149: 561-70.
71. Reboiras MD, Miller MJ and Jones MN. Liposome adsorption to Candida albicans. Colloids Surfaces B 1997; 9: 101-7.
72. Drulis-Kawa Z, Gubernator J, Dorotkiewicz-Jach A, et al. The interaction between Pseudomonas aeruginosa cells and cationic PC: Chol: DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cells. Int J Pharm 2009; 367: 211-9.
73. Drulis-Kawa Z, Gubernator J, Dorotkiewicz-Jach A, et al. In vitro antimicrobial activity of liposomal meropenem against Pseudomonas aeruginosa strains. Int J Pharm 2006; 315: 59-66.
74. Drulis-Kawa Z, Gubernator J, Dorotkiewicz-Jach A, et al. A comparison of the in vitro antimicrobial activity of liposomes containing meropenem and gentamicin. Cell Mole Biol Lett 2006; 11: 360-75.
75. Gubernator J, Drulis-Kawa Z, Dorotkiewicz-Jach A, et al. In vitro antimicrobial activity of liposomes containing Ciprofloxacin, Meropenem and Gentamicin against Gram-negative clinical bacterial strains. Lett Drug Des Discov 2007; 4: 297-304.
76. Papp-Wallace KM, Endimiani A, Taracila MA, et al. Carbapenems: Past, present, and future. Antimicrob Agents Chemotherap 2011; 55: 4943-60.
77. LeBel M. Ciprofloxacin: chemistry, mechanism of action, resistance, antimicrobial spectrum, pharmacokinetics, clinical trials, and adverse reactions. Pharmacotherapy 1988; 8: 3-33.
78. Gamazo C, Prior S, Concepción Lecároz M, et al. Biodegradable gentamicin delivery systems for parenteral use for the treatment of intracellular bacterial infections. Expert Opin Drug Deliv 2007; 4: 677-88.
79. Jia Y, Joly H, Omri A. Characterisation of the interaction between liposomal formulations and Pseudomonas aeruginosa. J Liposome Res 2010; 20: 134-46.
80. Jia Y, Joly H, Leek DM, et al. The effect of aminoglycoside antibiotics on the thermodynamic properties of liposomal vesicles. J Liposome Res 2010b; 20: 84-96.
81. Jia Y, Joly H, Omri A. Liposomes as a carrier for gentamicin delivery: Development and evaluation of the physicochemical properties. Int J Pharm 2008; 359: 254-63.
82. Mugabe C, Azghani AO, Omri A. Preparation and characterisation of dehydration-rehydration vesicles loaded with aminoglycoside and macrolide antibiotics. Int J Pharm 2006; 307: 244-50.
83. Omri A, Suntres ZE, Shek PN. Enhanced activity of liposomal polymyxin B against Pseudomonas aeruginosa in a rat model of lung infection. Biochem Pharmacol 2002; 64: 1407-13.
84. Alipour M, Halwani M, Omri A, et al. Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains. Int J Pharm 2008; 355: 293-8.
85. Rukholm G, Mugabe C, Azghani AO, et al. Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: A timekill study. Int J Antimicrob Agents 2006; 27: 247-52.
86. Mugabe C, Azghani AO, Omri A. Liposome-mediated gentamicin delivery: development and activity against resistant strains of Pseudomonas aeruginosa isolated from cystic fibrosis patients. J Antimicrob Chemotherap 2005; 55: 269-71.
87. Alipour M, Suntres ZE, Omri A. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J Antimicrob Chemotherap 2009; 64: 317-25.
88. Alipour M, Dorval C, Suntres ZE, et al. Bismuth-ethanedithiol incorporated in a liposome-loaded tobramycin formulation modulates the alginate levels in mucoid Pseudomonas aeruginosa. J Pharm Pharmacol 2011; 63: 999-1007.
89. Alipour M, Suntres ZE, Lafrenie RM, et al. Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by coencapsulation of bismuth-ethanedithiol with tobramycin in liposomes. J Antimicrob Chemotherap 2010; 65: 684-93.
90. Halwani M, Hebert S, Suntres ZE, et al. Bismuth-thiol incorporation enhances biological activities of liposomal tobramycin against bacterial biofilm and quorum sensing molecules production by Pseudomonas aeruginosa. Int J Pharm 2009; 373: 141-6.
91. Halwani M, Blomme S, Suntres ZE, et al. Liposomal bismuthethanedithiol formulation enhances antimicrobial activity of tobramycin. Int J Pharm 2008; 358: 278-84.
92. Halwani M, Mugabe C, Azghani AO, et al. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. J Antimicrob Chemother 2007; 60: 760-9.
93. Alhariri M, Omri A. Efficacy of liposomal bismuth-ethanedithiolloaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection. Antimicrob Agents Chemother 2013; 54: 569-78.
94. Alhajlan M, Alhariri M, Omri A. Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors. Antimicrob Agents Chemother 2013; 57: 2694-704.
95. Alipour M, Suntres ZE, Halwani M, et al. Activity and interactions of liposomal antibiotics in presence of polyanions and sputum of patients with Cystic Fibrosis. PLoS ONE 2009a; 4: e5724 doi: 10. 1371/journal. pone. 0005724.
96. Mitsopoulos P, Omri A, Alipour M, et al. Effectiveness of liposomal-N-acetylcysteine against LPS-induced lung injuries in rodents. Int J Pharm 2008; 363: 106-111.
97. Mehnert W, Mäder K. Solid lipid nanoparticles: Production, characterisation and applications. Adv Drug Deliv Rev 2012; 64: 83-101.
98. Cavalli R, Gasco MR, Chetoni P, et al. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm 2002; 238: 241-5.
99. Kim JK, Park JS, Kim CK. Development of a binary lipid nanoparticles formulation of itraconazole for parenteral administration and controlled release. Int J Pharm 2010; 383: 209-15.
100. Xie S, Zhu L, Dong Z, et al. Preparation, characterisation and pharmacokinetics of enrofloxacin-loaded solid lipid nanoparticles: Influence of fatty acids. Colloids Surf B 2011; 83: 382-7.
101. Garg A, Singh S. Enhancement in antifungal activity of eugenol in immunosuppressed rate through lipid nanocarriers. Colloids Surf B 2011; 87: 280-8.
102. Sandri G, Bonferoni MC, D'Autilia F, et al. Wound dressings based on silver sulfadiazine solid lipid nanoparticles for tissue repairing. Eur J Pharm Biopharm 2013; 84: 84-90.
103. Lawrence MJ, Rees GD. Microemulsion-based media as novel drug delivery systems. Adv Drug Deliv Rev 2012; 64: 175-93.
104. Fanun M. Microemulsions as delivery systems. Curr Opin Colloid Interface Sci 2012; 17: 306-13.
105. Narang AS, Delmarre D, Gao D. Stable drug encapsulation in micelles and microemulsions. Int J Pharm 2007; 345: 9-25.
106. Spernath A, Aserin A. Microemulsions as carriers for drugs and nutraceuticals. Adv Colloid interface Sci 2006; 128-130: 47-64.
107. Patel MR, Patel RB, Parikh JR, et al. Effect of formulation components on the in vitro permeability of microemulsion drug delivery system of fluconazole. AAPS Pharm Sci Tech 2009; 10: 917-23.
108. Patel MR, Patel RB, Parikh JR, et al. Investigating effect of microemulsion components: In vitro permeation of ketoconazole. Pharm Dev Technol 2011; 16: 250-8.
109. Kumar A, Agarwal SP, Ahuja A, et al. Preparation, characterisation and in vitro antimicrobial assessment of nanocarriers based formulation of nadifloxacin for acne treatment. Pharmazie 2011; 66: 111-4.
110. Mehta SK, Kaur G, Bhasin KK. Analysis of tween based microemulsions in the presence of TB drug rifampicin. Colloids Surf B 2007; 60: 95-104.
111. Mehta SK, Kaur G, Bhasin KK. Tween-embedded microemulsions-Physicochemical and spectroscopic analysis for antitubercular drugs. AAPS Pharm Sci Tech 2010; 11: 143-53.
112. Mehta SK, Kaur G, Bhasin KK. Entrapment of multiple anti-Tb drugs in microemulsion systems: Quantitative analysis, stability and in vitro release studies. J Pharma Sci 2010b; 99: 1896-911.
113. Ramalingam K, Frohlich NC, Lee VA. Effect of nanoemulsion of dental unit waterline biofilm. J Dent Sci 2013; 8: 333-336.
114. Ramalingam K, Amaechi BT, Rawls RH, et al. Antimicrobial activity of nanoemulsion on cariogenic planktonic and biofilm organisms. Arch Oral Biol 2012; 57: 15-22.
115. Ramalingam K, Amaechi BT, Rawls RH, et al. Antimicrobial activity of nanoemulsion on cariogenic Streptococcus mutans. Arch Oral Biol 2011; 56: 437-45.
116. Ferreira JP, Alves D, Neves O, et al. Effect of the components of two antimicrobial emulsions on food-borne pathogens. Food Control 2010; 21: 227-30.
117. Teixeira PC, Leite GM, Domingues RJ, et al. Antimicrobial effect of microemulsion and a nanoemulsion on enteric and other pathogens and biofilms. Int J Food Microbiol 2007; 118: 15-9.
118. Zhang H, Cui Y, Zhu S, et al. Characterisation and antimicrobial activity of a pharmaceutical microemulsion. Int J Pharm 2010; 395: 154-60.
119. Fu X, Feng F, Huang B. Physicochemical characterisation and evaluation of a microemulsion system for antimicrobial activity of glycerol monolaurate. Int J Pharm 2006; 321: 171-5.
120. Al-Adham ISI, Al-Hmoud, Khalil E, et al. Microemulsions are highly effective anti-biofilm agents. Lett Appl Microbiol 2003; 36: 97-100.
121. Al-Adham ISI, Ashour H, Al-Kaissi E, et al. Studies on the kinetics of killing and the proposed mechanism of action of microemulsions against fungi. Int J Pharm 2013; 454: 226-32.
122. Jumaa M, Furkert FH, Müller BW. A new lipid emulsion formulation with high antimicrobial efficacy using chitosan. Eur J Pharm Biopharm 2002: 115-23.
123. Donsì F, Annunziata M, Vincensi M, et al. Design of nanoemulsion-based delivery systems of natural antimicrobials: Effect of the emulsifier. J Biotechnol 2012; 159: 342-50.
124. Liu Y, Lim J, Teoh S-H. Review: Development of clinically relevant scaffolds for vascularised bone tissue engineering. Biotechnol Adv 2013; 31: 688-705.
125. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barrier. Adv Drug Deliv Rev 2012; 64: 557-70.
126. Tessmar JK, Göpferich AM. Matrices and scaffolds for protein delivery in tissue engineering. Adv Drug Deliv Rev 2007; 59: 274-91.
127. Rasal RM, Janorkar AV, Hirt DE. Poly(lactic acid) modifications. Progress Polymer Sci 2010; 35: 338-56.
128. Woodruff MA, Hutmacher DW. The return on a forgotten polymer-Polycaprolactone in the 21st century. Prog Polym Sci 2010; 35: 1217-56.
129. Gupta AP, Kumar V. New emerging trends in synthetic biodegradable polymers-Polylactide: A critique. Eur Polym J 2007; 43: 4053-74.
130. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. Colloids Surf B 2010; 75: 1-18.
131. Pinto Reis C, Neufeld RJ, Ribeiro AJ, et al. Nanoencapsulation I: Methods for preparation of drug-loaded polymeric nanoparticles. Nanomedicine: Nanotechnology, Biol Med 2006; 2: 8-21.
132. Muñoz-Bonilla A, Fernández-García M. Polymeric materials with antimicrobial activity. Prog Polym Sci 2012; 37: 281-339.
133. Cheow WS, Hadinoto K. Lipid-polymer hybrid nanoparticles with rhamnolipid-triggered release capabilities as anti-biofilm drug delivery vehicles. Particuology 2012; 10: 327-33.
134. Cheow WS, Chang MW, Hadinoto K. The roles of lipid in antibiofilm efficacy of lipid-polymer hybrid nanoparticles encapsulating antibiotics. Colloids Surf A 2011; 389: 158-65.
135. Yue IC, Poff J, Cortés ME, et al. A novel polymeric chlorhexidine delivery device for the treatment of periodontal disease. Biomaterials 2004; 25: 3743-50.
136. Pichavant L, Amador G, Jacqueline C, et al. pH-controlled delivery of gentamicin sulfate from orthopaedic devices preventing nosocomial infections. J Control Release 2012; 162: 373-81.
137. Muñoz-Muñoz F, Ruiz J-C, Alvarez-Lorenzo C, et al. Novel interpenetrating smart polymer networks grafted onto polypropylene by gamma radiation for loading and delivery of vancomycin. Eur Polym J 2009; 45: 1859-67.
138. Ruiz J-C, Alvarez-Lorenzo C, Taboada P, et al. Polypropylene grafted with smart polymers (PNIPAAm/PAAc) for loading and controlled release of vancomycin. Eur J Pharm Biopharm 2008; 70: 467-77.
139. Schaer TP, Stewart S, Hsu BB, et al. Hydrophobic polycationic coatings that inhibit biofilms and support bone healing during infection. Biomaterials 2012; 33: 1245-54.
140. Anderson EM, Noble ML, Garty S, et al. Sustained release of antibiotic from poly(2-hydroxyethyl methacrylate) to prevent blinding infections after cataract surgery. Biomaterials 2009; 30: 5675-81.
141. Costache MC, Vaughan AD, Qu H, et al. Tyrosine-derived polycarbonate-silica xerogel nanocomposites for controlled drug delivery. Acta Biomater 2013; 9: 6544-52.
142. Sun X, Cao Z, Yeh C-K, et al. Antifungal activity, biofilmcontrolling effect and biocompatibility of poly(N-vinyl-2-pyrrolidinone)-grafted denture materials. Colloids Surf B 2013; 110: 96-104.
143. Cortizo MC, Oberti TG, Cortizo MS, et al. Chlorhexidine delivery system from titanium/polybenzyl acrylate coating: Evaluation of cytotoxicity and early bacterial adhesion. J Dent 2012; 40: 329-37.
144. Nanjwade BK, Bechra HM, Derkar GK, et al. Dendrimers: Emerging polymers for drug-delivery systems. Eur J Pharm Sci 2009; 38: 185-93.
145. Gupta U, Agashe HB, Asthana A, et al. A review of in vitro-in vivo investigations on dendrimers: The novel nanoscopic drug carriers. Nanomedicine: Nanotechnol, Biol Med 2006; 2: 66-73.
146. Svenson S. Dendrimers as versatile platform in drug delivery applications. Eur J Pharm Biopharm 2009; 71: 445-62.
147. Janiszewska J, Swieton J, Lipkowski AW, et al. Low molecular mass peptide dendrimers that express antimicrobial properties. Bioorganic Med Chem Lett 2003; 13: 3711-3.
148. Johansson EMV, Crusz SA, Kolomiets E, et al. Inhibition and dispersion of Pseudomonas aeruginosa biofilms by glycopeptide dendrimers targeting the fucose-specific lectin LecB. Chem Biol 2008; 15: 1249-57.
149. Cheng Y, Qu H, Ma M, et al. Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: An in vitro study. Eur J Med Chem 2007; 42: 1032-8.
150. Ma M, Cheng Y, Xu Z, et al. Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug. Eur J Med Chem 2007; 42: 93-98.
151. Refat MS, El-Deen IM, Grabchev I, et al. Spectroscopic characterisations and biological studies on newly synthesised Cu2+ and Zn2+ complexes of first and second generation dendrimers. Spectrochim Acta A Mol Biomol Spectrosc 2009; 72: 772-82.
152. O'Gorman J, Humphreys H. Application of copper to prevent and control infection. Where are we now? J Hosp Infect 2012; 81: 217-23.
153. Stanić V, Dimitrijević S, Antić-Stanković J, et al. Synthesis, characterisation and antimicrobial activity of copper and zinc-doped hydroxyapatite nanopowders. Appl Surface Sci 2010; 256: 6083-9.
154. Phan T-N, Buckner T, Sheng J, et al. Physiological actions of zinc related to inhibition of acid and alkali production by oral streptococci in suspensions and biofilms. Oral Microbiol Immunol 2004; 19: 31-8.
155. Concheiro A, Alvarez-Lorenzo C. Chemically cross-linked and grafted cyclodextrin hydrogels: From nanostructures to drugeluting medical devices. Adv Drug Deliv Rev 2013; 65: 1188-203.
156. Kurkov SV, Loftsson T. Cyclodextrins. Int J Pharm 2013; 453: 167-80.
157. eMC [homepage on the Internet], the electronic medicines compendium [cited 31st August 2013]. Available from: http://www. medicines. org. uk/emc/default. asp.
158. Hanakova A, Bogdanova K, Tomankova K, et al. The application of antimicrobial photodynamic therapy on S. aureus and E. coli using porphyrin photosensitisers bound to cyclodextrin. Microbiol Res 2013; 169: 163-70.
159. Aleem O, Kuchekar B, Pore Y, et al. Effect of cyclodextrin and hydroxypropyl cyclodextrin complexation on physicochemical properties and antimicrobial activity of cefdinir. J Pharm Biomed Anal 2008; 47: 535-40.
160. He ZX, Want ZH, Zhang HH, et al. Doxycycline and hydroxypropyl-cyclodextrin complex in poloxamers thermal sensitive hydrogel for ophthalmic delivery. Acta Pharm Sin 2011; 1: 254-60.
161. Alejandra RC, Cristina C, Margarita CM, et al. Methods for the preparation of doxycycline-loaded PHB micro-and nano-spheres. Eur Polym J 2013; 49: 3501-11.
162. Feng K, Sun H, Bradley MA, et al. Novel antibacterial nanofibrous PLLA scaffolds. J Controlled Release 2010; 146: 363-9.
163. Jansook P, Loftsson T. CDs as solubilisers: Effects of excipients and competing drugs. Int J Pharm 2009; 379: 32-40.
164. Nava-Ortiz CAB, Burillo G, Concheiro A, et al. Cyclodextrinfunctionalized biomaterials loaded with micronazole prevent Candida albicans biofilm formation in vitro. Acta Biomater 2010; 6: 1398-404.
165. Gharbi A, Humblot V, Turpin F, et al. Elaboration of antibiofilm surfaces functionalised with antifingal-cyclodextrin inclusion complexes. FEMS Immunol Med Microbiol 2012; 65: 257-69.
166. Rosa dos Santos JF, Torres-Labandeira JJ, Matthijs N, et al. Functionalisation of acrylic hydrogels with α-, β-or β-cyclodextrin modulates protein adsorption and antifungal activity delivery. Acta Biomater 2010; 6: 3919-26.
167. Blanco-Fernandez B, Lopez-Viota M, Concheiro A, et al. Synergistic performance of cyclodextrin-agar hydrogels for ciprofloxacin delivery and antimicrobial effect. Carbohydr Polym 2011; 85: 765-74.
168. Rai M, Yadav A, Gade A. Silver nanoparticles as a new generation of antimicrobials. Biotechnol Adv 2009; 27: 76-83.
169. Kwakye-Awuah B, Kenward MA, Williams C, et al. Antimicrobial action and efficiency of silver-loaded zeolite X. J Appl Microbiol 2008; 104: 1516-24.
170. Low WL, Martin C, Kenward MA. Antimicrobial Activity of Zeolite Exchanged and Liposome Encapsulated Silver Ions. Proc Int Symp Control Release Bioactive Mats 2010; 37: 18.
171. Ravindran A, Chandran P, Khan SS. Biofuntionalised silver nanoparticles: Advances and prospects. Colloids and Surfaces B: Biointerfaces 2013; 105: 342-52.
172. Gunasekaran T, Nigusse T, Dhanaraju MD. Silver nanoparticles as real topical bullets for wound healing. J Am Coll Clin Wound Spec 2012; 3: 82-96.
173. Wani IA, Khatoon S, Ganguly A, et al. Structural characterisation and antimicrobial properties of silver nanoparticles prepared by inverse microemulsion method. Colloids and Surfaces B: Biointerfaces 2013; 101: 243-50.
174. Mohantry S, Mishra S, Jena P, et al. An investigation on the antibacterial, cytotoxic and antibiofilm efficacy of starch-stabilised silver nanoparticles. Nanomedicine: Nanotechnol, Biol Med 2012; 8: 916-24.
175. Radzig MA, Nadtochenko VA, Koksharova OA, et al. Antibacterial effects of silver nanoparticles on Gram-negative bacteria: Influence on the growth and biofilms formation, mechanism of action. Colloids and Surfaces B: Biointerfaces 2013; 102: 300-6.
176. Park H-J, Park S, Roh J, et al. Biofilm-inactivating activity of silver nanoparticles: A comparison with silver ions. J Ind Eng Chem 2013; 19: 614-9.
177. Rana S, Bajaj A, Mout R, et al. Monolayer coated gold nanoparticles for delivery applications. Adv Drug Deliv Rev 2012; 64: 200-16.
178. Pissuwan D, Niidome T, Cortie MB. The forthcoming applications of gold nanoparticles in drug and gene delivery systems. J Control Release 2011; 149: 65-71.
179. Ghosh P, Han G, De M, et al. Gold nanoparticles in delivery applications. Adv Drug Deliv Rev 2008; 60: 1307-15.
180. Vigderman L, Zubarev ER. Therapeutic platforms based on gold nanoparticles and their covalent conjugates with drug molecules. Adv Drug Deliv Rev 2013; 65: 663-76.
181. Kumar A, Zhang X, Liang XJ. Gold nanoparticles: Emerging paradigm for targeted drug delivery systems. Biotechnol Adv 2013; 31: 593-606.
182. Ahmad T, Wani IA, Manzoor N, et al. Biosynthesis, structural characterisation and antimicrobial activity of gold and silver nanoparticles. Colloids and Surfaces B: Biointerfaces 2013; 107: 227-34.
183. Guerra R, Lima E, Guzmán A. Antimicrobial supported nanoparticles: Gold versus silver for the cases of Escherichia coli and Salmonella typhi. Micropor Mesopor Mat 2013; 170: 62-6.
184. Geethalakshmi R, Sarada DVL. Characterisation and antimicrobial activity of gold and silver nanoparticles synthesised using saponin isolated from Trianthema decandra L. Ind Crop Prod 2013; 51: 107-15.
185. Naik AJT, Ismail S, Kay C, et al. Antimicrobial activity of polyurethane embedded with methylene blue and gold nanoparticles against Staphylococcus aureus; illuminated with white light. Mater Chem Phys 2011; 129: 446-50.
186. Perni S, Piccirillo C, Pratten J, et al. The antimicrobial properties of light-activated polymers containing methylene blue and gold nanoparticles. Biomaterials 2009; 30: 89-93.
187. Ruparelia JP, Chatterjee AK, Duttagupta SP, et al. Strain specificity in antimicrobial activity of silver and copper nanoparticles. Acta Biomater 2008; 4: 707-16.
188. Khan ST, Ahamed M, Al-Khedhairy A, et al. Biocidal effect of copper and zinc oxide nanoparticles on human oral microbiome and biofilm formation. Mater Lett 2013; 97: 67-70.
189. Chowdhury MNK, Beg MDH, Khan MR, et al. Synthesis of copper nanoparticles and their antimicrobial performances in natural fibres. Mater Lett 2013; 98: 26-9.
190. Ramyadevi J, Jeyasubramanian K, Marikani A, et al. Synthesis and antimicrobial activity of copper nanoparticles. Mater Lett 2012; 71: 114-6.
191. Veerapandian M, Sadhasivam S, Choi J, et al. Glucosamine functionalised copper nanoparticles: Preparation, characterisation and enhancement of anti-bacterial activity by ultraviolet irradiation. Chem Eng J 2012; 209: 558-67.
192. Keegan G, Smart J, Ingram M, et al. An in vitro assessment of bioadhesive zinc/carbomer complexes for antimicrobial therapy within the oral cavity. Int J Pharm 2007; 340: 92-96.
193. Sheng J, Nguyen PTM, Marquis RE. Multi-target antimicrobial actions of zinc against anaerobes. Arch Oral Biol 2005; 50: 747-57.
194. Xie Y, He Y, Irwin PL, et al. Antibacterial activity and mechanism of action of zinc oxide nanoparticles against Campylobacter jejuni. Appl Environ Microbiol 2011; 77: 2325-31.
195. Yousef JM, Danial EN. In vitro antibacterial activity and minimum inhibitory concentration of zinc oxide and nanoparticle zinc oxide against pathogenic strains. J Health Sci 2012; 2: 38-42.
196. Yamamoto O. Influence of particle size on the antibacterial activity of zinc oxide. Int J Inorg Mater 2001; 3: 643-6.
197. Khan A, Mehmood S, Shafiq M, et al. Structural and antimicrobial properties of irradiated chitosan and its complexes with zinc. Radiat Phys Chem 2013b; 91: 138-42.
198. Musk DJ, Banko DA, Hergenrother PJ. Iron salts perturb biofilm formation and disrupt existing biofilms of Pseudomonas aeruginosa. Chem Biol 2005; 12: 789-96.
199. Subbiahdoss G, Sharifi S, Grijpma DW, et al. Magnetic targeting of surface-modified superparamagnetic iron oxide nanoparticles yields antibacterial efficacy against biofilms of gentamicin-resistant staphylococci. Acta Biomater 2012; 8: 2047-55.